Skip to main content

Invitrogen Inks Drug-Discovery Collaboration with Chinese Drug-Screening Concern

NEW YORK , Oct. 31 (GenomeWeb News) - Invitrogen will provide its drug-discovery technologies to the National Center for Drug Screening, a Shanghai-based public technology organization that specializes in screening new drugs in China, the company said today.

 

The deal calls for Invitrogen to contribute drug-discovery technologies such as GeneBlazer and Polar Screen, and to help the NationalCenter for Drug Screening develop new assays and techniques specific to the collaboration, the company said.

 

Specific terms of the arrangement were not disclosed.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.